# Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

> **NCT01456013** · PHASE3 · UNKNOWN · sponsor: **CardioRenal Systems, Inc.** · enrollment: 326 (actual)

## Conditions studied

- Contrast Induced Nephropathy

## Interventions

- **DEVICE:** RenalGuard Therapy
- **DRUG:** Standard Therapy

## Key facts

- **NCT ID:** NCT01456013
- **Lead sponsor:** CardioRenal Systems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2018-03
- **Final completion:** 2024-12
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456013, "Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01456013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*